pimurutamab
- Generic Name
- pimurutamab
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
Phase 2
Active, not recruiting
- Conditions
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT05513573
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 24
- Registration Number
- NCT05360368
- Locations
- 🇨🇳
Fudan University shanghai cancer center, Shanghai, China
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Phase 2
- Conditions
- Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 20
- Registration Number
- NCT05354700
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT05290220
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
Phase 2
- Conditions
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
- Interventions
- Drug: HLX07+HLX10+oxaliplatin+capecitabine
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 40
- Registration Number
- NCT05246982
- Locations
- 🇨🇳
Gansu Wuwei Tumor Hospital, Wuwei, Gansu, China
🇨🇳Fudan University shanghai cancer center, Shanghai, China
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 50
- Registration Number
- NCT05239650
The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 20
- Registration Number
- NCT05238363
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
Phase 2
Recruiting
- Conditions
- ESCC or Esophageal Adenosquamous Carcinoma
- Interventions
- Drug: HLX07+HLX10+ Cisplatin+5-FU
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT05221658
- Locations
- 🇨🇳
Hunan Cancer Hospitla, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Anyang Cancer Hospital, Anyang, Hebei, China
A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression
Phase 2
- Conditions
- HLX07, nsqNSCLC, High EGFR Expression
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT05215925
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Phase 2
Active, not recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 131
- Registration Number
- NCT04297995
- Locations
- 🇨🇳
Shanghai Henlius Biotech Inc., Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath